130 related articles for article (PubMed ID: 28050723)
1. Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Model; 2017 Jan; 23(1):18. PubMed ID: 28050723
[TBL] [Abstract][Full Text] [Related]
2. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
3. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling.
Berinyuy E; Soliman MES
Interdiscip Sci; 2017 Sep; 9(3):406-418. PubMed ID: 27165479
[TBL] [Abstract][Full Text] [Related]
5. Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors.
Andrianov AM; Nikolaev GI; Shuldov NA; Bosko IP; Anischenko AI; Tuzikov AV
J Biomol Struct Dyn; 2022 Oct; 40(16):7555-7573. PubMed ID: 33855929
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study.
Andrianov AM; Kashyn IA; Tuzikov AV
J Biomol Struct Dyn; 2014 Dec; 32(12):1993-2004. PubMed ID: 24251545
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies.
Liu S; Fan S; Sun Z
J Mol Model; 2003 Oct; 9(5):329-36. PubMed ID: 14517611
[TBL] [Abstract][Full Text] [Related]
8. E-pharmacophore based screening to identify potential HIV-1 gp120 and CD4 interaction blockers for wild and mutant types.
Chandra I; Prabhu SV; Nayak C; Singh SK
SAR QSAR Environ Res; 2021 May; 32(5):353-377. PubMed ID: 33832362
[TBL] [Abstract][Full Text] [Related]
9. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action.
Langley DR; Kimura SR; Sivaprakasam P; Zhou N; Dicker I; McAuliffe B; Wang T; Kadow JF; Meanwell NA; Krystal M
Proteins; 2015 Feb; 83(2):331-50. PubMed ID: 25401969
[TBL] [Abstract][Full Text] [Related]
10. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
11. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M
ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling on human CCR5 receptors and complex with CD4 antigens and HIV-1 envelope glycoprotein gp120.
Yang J; Liu CQ
Acta Pharmacol Sin; 2000 Jan; 21(1):29-34. PubMed ID: 11263244
[TBL] [Abstract][Full Text] [Related]
13. Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120.
Hsu ST; Bonvin AM
Proteins; 2004 May; 55(3):582-93. PubMed ID: 15103622
[TBL] [Abstract][Full Text] [Related]
14. Systematic protein-protein docking and molecular dynamics studies of HIV-1 gp120 and CD4: insights for new drug development.
Chong Teoh T; Heidelberg T; Rizman-Idid M
Daru; 2011; 19(6):469-75. PubMed ID: 23008694
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
16. Mutation in the D1 domain of CD4 receptor modulates the binding affinity to HIV-1 gp120.
Shao J; Liu G; Lv G
RSC Adv; 2023 Jan; 13(3):2070-2080. PubMed ID: 36712621
[TBL] [Abstract][Full Text] [Related]
17. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
[TBL] [Abstract][Full Text] [Related]
18. Prediction of HIV-1 entry inhibitors neomycin-arginine conjugates interaction with the CD4-gp120 binding site by molecular modeling and multistep docking procedure.
Berchanski A; Lapidot A
Biochim Biophys Acta; 2007 Sep; 1768(9):2107-19. PubMed ID: 17560540
[TBL] [Abstract][Full Text] [Related]
19. Design of human immunodeficiency virus-1 neutralizing peptides targeting CD4-binding site: An integrative computational biologics approach.
Vivekanandan S; Vetrivel U; Hanna LE
Front Med (Lausanne); 2022; 9():1036874. PubMed ID: 36465923
[TBL] [Abstract][Full Text] [Related]
20. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
